Publication Information (EuropePMC) | |
Title | Genetic and Circulating Biomarker Data Improve Risk Prediction for Pancreatic Cancer in the General Population. |
PubMed ID | 32321713(Europe PMC) |
doi | 10.1158/1055-9965.epi-19-1389 |
Publication Date | April 22, 2020 |
Journal | Cancer Epidemiol Biomarkers Prev |
Author(s) | Kim J, Yuan C, Babic A, Bao Y, Clish CB, Pollak MN, Amundadottir LT, Klein AP, Stolzenberg-Solomon RZ, Pandharipande PV, Brais LK, Welch MW, Ng K, Giovannucci EL, Sesso HD, Manson JE, Stampfer MJ, Fuchs CS, Wolpin BM, Kraft P. |
Polygenic Score ID & Name | PGS Publication ID (PGP) | Reported Trait | Mapped Trait(s) (Ontology) | Number of Variants |
Ancestry distribution GWAS Dev Eval |
Scoring File (FTP Link) |
---|---|---|---|---|---|---|
PGS000663 (wGRS22) |
PGP000123 | Kim J et al. Cancer Epidemiol Biomarkers Prev (2020) |
Pancreatic cancer | pancreatic carcinoma | 22 | - |
https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000663/ScoringFiles/PGS000663.txt.gz |
PGS Performance Metric ID (PPM) |
Evaluated Score |
PGS Sample Set ID (PSS) |
Performance Source | Trait |
PGS Effect Sizes (per SD change) |
Classification Metrics | Other Metrics | Covariates Included in the Model |
PGS Performance: Other Relevant Information |
---|---|---|---|---|---|---|---|---|---|
PPM001367 | PGS000663 (wGRS22) |
PSS000598| European Ancestry| 1,591 individuals |
PGP000123 | Kim J et al. Cancer Epidemiol Biomarkers Prev (2020) |
Reported Trait: Pancreatic cancer | OR: 1.37 [1.23, 1.53] | — | — | — | Cross validation approach-testing sample = 20% |
PPM001368 | PGS000663 (wGRS22) |
PSS000597| European Ancestry| 956 individuals |
PGP000123 | Kim J et al. Cancer Epidemiol Biomarkers Prev (2020) |
Reported Trait: Pancreatic cancer (0-10 years of follow-up) | OR: 1.46 [1.27, 1.68] | — | — | — | Cross validation approach-testing sample = 20% |
PPM001369 | PGS000663 (wGRS22) |
PSS000598| European Ancestry| 1,591 individuals |
PGP000123 | Kim J et al. Cancer Epidemiol Biomarkers Prev (2020) |
Reported Trait: Pancreatic cancer | OR: 1.37 [1.22, 1.53] | AUROC: 0.65 | — | matching factors, age, cohort (also gender), race/ethnicity, smoking status, fasting status, month/year of blood collection, body mass index, waist-to-hip ratio, diabetic status | Cross validation approach-testing sample = 20% |
PPM001370 | PGS000663 (wGRS22) |
PSS000597| European Ancestry| 956 individuals |
PGP000123 | Kim J et al. Cancer Epidemiol Biomarkers Prev (2020) |
Reported Trait: Pancreatic cancer (0-10 years of follow-up) | OR: 1.44 [1.25, 1.67] | AUROC: 0.67 | — | matching factors, age, cohort (also gender), race/ethnicity, smoking status, fasting status, month/year of blood collection, body mass index, waist-to-hip ratio, diabetic status | Cross validation approach-testing sample = 20% |
PGS Sample Set ID (PSS) |
Phenotype Definitions and Methods | Participant Follow-up Time | Sample Numbers | Age of Study Participants | Sample Ancestry | Additional Ancestry Description | Cohort(s) | Additional Sample/Cohort Information |
---|---|---|---|---|---|---|---|---|
PSS000597 | In this study, cases were incident patients with primary pancreatic adenocarcinoma ascertained between 1984 and 2010 through self- report, report of next-of-kin, or death certificates and confirmed by medical record review and tumor registry data. Cases Diagnosed within 10 years of blood collection. | Mean = 10.0 years | [ ,
28.1 % Male samples |
— | European | — | HPFS, NHS, PHS, WHI | Overlap with GWAS samples (percentage unknown). Cross validation approach used (20% as testing sample) |
PSS000598 | In this study, cases were incident patients with primary pancreatic adenocarcinoma ascertained between 1984 and 2010 through self- report, report of next-of-kin, or death certificates and confirmed by medical record review and tumor registry data. | — | [ ,
33.4 % Male samples |
— | European | — | HPFS, NHS, PHS, WHI | Overlap with GWAS samples (percentage unknown). Cross validation approach used (20% as testing sample) |